US Patent

US12453758 — Method of using a GIP/GLP1 co-agonist for diabetes

Method of Use · Assigned to Eli Lilly and Co · Expires 2039-07-22 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating type 2 diabetes using a specific dosing regimen of a GIP/GLP-1 peptide.

USPTO Abstract

The present invention provides methods of treating type 2 diabetes (T2D) using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 10:1 GIP to GLP-1. Furthermore, the present invention provides methods of treating T2D using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 5:1 GIP to GLP-1. Also, the present invention provides methods of inducing T2D remission using a novel dosing regimen of a GIP:GLP-1 Peptide. The present invention also provides methods of treating obesity using a novel dosing regimen of a GIP:GLP-1 Peptide.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4311 — Mounjaro
U-4310 — Mounjaro
U-4308 — Mounjaro
U-4311 — Mounjaro
U-4309 — Mounjaro
U-4310 — Mounjaro
U-4311 — Mounjaro
U-4311 — Mounjaro
U-4311 — Mounjaro
U-4310 — Mounjaro
U-4310 — Mounjaro
U-4310 — Mounjaro
U-4310 — Mounjaro
U-4310 — Mounjaro
U-4310 — Mounjaro
U-4310 — Mounjaro
U-4311 — Mounjaro
U-4311 — Mounjaro
U-4308 — Mounjaro
U-4311 — Mounjaro
U-4311 — Mounjaro
U-4311 — Mounjaro
U-4311 — Mounjaro
U-4311 — Mounjaro

Patent Metadata

Patent number
US12453758
Jurisdiction
US
Classification
Method of Use
Expires
2039-07-22
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.